Noberasco C, Bajetta E, Zilembo N, Di Leo A, Cappuzzo F, Bartoli C, Bono A, Bichisao E
Medical Oncology Division B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.
Oncology. 1995 Nov-Dec;52(6):454-7. doi: 10.1159/000227510.
In order to assess the feasibility of a sequential hormonal treatment after tamoxifen failure, 24 postmenopausal advanced breast cancer patients (median age 60 years; ECOG PS < or = 1) were treated with formestane (4-hydroxyandrostenedione) 250 mg i.m. fortnightly; 19 patients were estrogen receptor-positive. The sites of metastatic disease were soft tissue in 22 patients, viscera in 9 and bone in 18. The patients were considered evaluable for tumor response after four doses of formestane. Objective responses were observed in 8/24 patients (33%) with one complete and seven partial responses. The median response duration was 9.5 months. The complete response was obtained on skin. We conclude that although the number of complete responses appears to be unsatisfactory, de novo tamoxifen-resistant breast cancer patients are suitable for further hormonal treatment with formestane.
为评估他莫昔芬治疗失败后序贯激素治疗的可行性，对24例绝经后晚期乳腺癌患者（中位年龄60岁；东部肿瘤协作组体能状态评分≤1）每两周肌肉注射250mg福美司坦（4-羟基雄烯二酮）进行治疗；19例患者雌激素受体阳性。转移病灶部位：22例患者为软组织，9例为内脏，18例为骨。在给予四剂福美司坦后，对患者的肿瘤反应进行评估。24例患者中有8例（33%）观察到客观反应，其中1例完全缓解，7例部分缓解。中位缓解持续时间为9.5个月。完全缓解出现在皮肤上。我们得出结论，尽管完全缓解的数量似乎不尽人意，但初治他莫昔芬耐药的乳腺癌患者适合进一步接受福美司坦激素治疗。
